# Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Canonical URL: https://biopharmsignal.com/news/ABSI/absci-reports-business-updates-and-first-quarter-2026-financial-and-operating-results
Ticker: ABSI
Company: Absci Corporation
Source: Absci Corporation
Published: 2026-05-07 20:06 EST
Original Source URL: https://investors.absci.com
## Summary

Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of

## Article Body
Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of
## Recent Company News
- 2026-05-07 20:06 EST — [Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/ABSI/absci-reports-business-updates-and-first-quarter-2026-financial-and-operating-results) — Source: Absci Corporation
- 2026-05-05 00:12 EST — [Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ABSI/absci-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Absci Corporation
- 2026-04-23 20:04 EST — [Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026](https://biopharmsignal.com/news/ABSI/absci-to-report-business-updates-and-first-quarter-2026-financial-and-operating-results-on-may-7-2026) — Source: Absci Corporation
- 2026-04-08 12:00 EST — [Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/ABSI/absci-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference) — Source: Absci Corporation
- 2026-03-24 20:05 EST — [Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results](https://biopharmsignal.com/news/ABSI/absci-reports-business-updates-and-fourth-quarter-and-full-year-2025-financial-and-operating-results) — Source: Absci Corporation
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)